Use Hospira Inc. story concurrently with your other holdings to enhance returns of your portfolios and to back test it against optimization strategy that fits your risk preferences.
This story from stocks.us.reuters.com contributed to next trading day price increase. The story delta to the next closing price was 1.01% . The story delta to the current price is 16.61% .
FiercePharma - May 16, 2012
Eloxatin managed to make the top 5 this time based on 2011, but 2012 may be another story. The drug goes off patent in August, and a slew of generics are already approved.
As per reports, it has been revealed that Hospira Inc. (HSP) has recalled one lot of Hydromorphone Hydrochloride Injection, as it contained more than desired opioid.
NASDAQ - May 15, 2012
(RTTNews.com) - Hospira Inc.(HSP) has initiated a nationwide voluntary recall of one lot of Hydromorphone Hydrochloride Injection 1 mg/ml, with the knowledge of the FDA, after it was found that the opioid analgesic injection contained more than the ...
USA 
Equity Search
Advanced Search
Market Screener
Adviser Directory
Suggest Portfolio
Backtest Watchlist
Analyze Correlations
View Transactions
Check Volatility
Import Equities
Summary
Fundamentals
Technicals
Performance
Valuation
Volatility
History
News
Management
Discussion
